Abstract:ID 87555 Poster Board 494 Bioactive compounds sometimes possess unfavorable properties for drug development due to on-target, off-tissue mediated side effects or poor pharmacological properties. Activation of drug targets expressed in tissues not involved in therapeutic responses can limit medical application. One solution is to use analogue(s) or fragments of bioactive drugs that become activated only at sites of interest. Herein we describe the development of fragments of a peptidic GPCR ligand that can react to form a bioactive product upon exposure to a dimerizing agent that stimulates in situ assembly. To enhance specificity, we developed methods for the directed delivery of such a dimerizing agent to cell types of choice. We sought to apply this approach for activation of the parathyroid hormone receptor-1 (PTHR1), which regulates skeletal development and mineral ion homeostasis. The prototypical peptide agonist of PTHR1 (PTH 1-34 ) was separated into two constituent fragments (PTH 1-11 and PTH 12-34 ), each of which possesses little to no biological activity alone. In situ synthesis of conjugates that resemble PTH 1-34 was achieved through peptide template-induced dimerization and click (azide-alkyne) reactions between the fragment peptides PTH 1-11 and PTH 12-34. Dimerization is facilitated through the binding of nanobodies (Nbs) to peptide tags as described below. Nbs are single antigen recognition domains of heavy-chain only antibodies, which exhibit specificity and affinity for biological macromolecules comparable to conventional antibodies. Templated dimerization was achieved by fusing PTH fragments containing click chemistry handles to one of two Nbs that bind to short peptide epitopes. A heterodimeric peptide (HDP), comprised of the two distinct Nb-binding peptide epitopes, was used to bring fusions comprised of Nbs and PTH fragments with complementary click handles, into proximity. HDP-induced co-localization was designed to trigger the click reaction within the cellular medium at high dilution. Gel electrophoresis analysis of the kinetics of the reaction between azide- and alkyne-functionalized Nbs showed that HDP-mediated dimerization accelerated reaction kinetics. In the context of a cell-based assays, PTH fragment-click handle-Nb conjugates were weakly active alone or when added in tandem. The addition of HDP to the tandem mixture resulted in strong activation (via in situ ligand assembly) of PTHR1. We further demonstrate that dimeric peptide-induced in situ assembly can be achieved with cell-type specificity and high efficiency via Nb-based delivery of dimerizing agent. Altogether, this approach entails a new strategy for in situ synthesis of a bioactive agonist from its inactive fragment peptides. These results offer a path towards in situ assembly of bioactive molecules based on targeted delivery of dimerizing agents. These findings, coupled with the modular and programmable nature of our strategy, suggest the possibility of engineering similar approaches for the targeted synthesis of a diverse range of clinically relevant molecules in various in vitro and in vivo settings. This research was supported by the Intramural Research Program of the NIH, The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Mono- and bi-specific nanobodies targeting the CUB domains of PCPE-1 reduce the proteolytic processing of fibrillar procollagens

Procollagen C-proteinase enhancer grasps the stalk of the C-propeptide trimer to boost collagen precursor maturation

Synergistic Effect of PCPE1 and Sfrp2 on the Processing of Procollagens Via BMP1.

Manipulation of Transgene Expression in Fibroblast Cells by a Multifunctional Linear-Branched Hybrid Poly(β-Amino Ester) Synthesized Through an Oligomer Combination Approach.

570 Blockade of the Inhibitory Collagen Receptor LAIR-1, PD-L1, and TGF-β Promotes Anti-Tumor Activity Through T Cell Activation and Myeloid Cell Polarization

Recombinant Collagen Engineered to Bind to Discoidin Domain Receptor Functions as a Receptor Inhibitor

Characterisation of a monoclonal antibody against native human type I collagen

Identification of HSP47 Binding Site on Native Collagen and Its Implications for the Development of HSP47 Inhibitors

Collagenase Nanocapsules: An Approach to Fibrosis Treatment

Tuning cellular response by modular design of bioactive domains in collagen

Targeting Collagen, Targeting with Collagen

Treatment of Collagen-Induced Arthritis with an Anti-Osteopontin Monoclonal Antibody Through Promotion of Apoptosis of Both Murine and Human Activated T Cells

TANGO1 inhibitors reduce collagen secretion and limit tissue scarring

Peptides and Peptidomimetics as Inhibitors of Enzymes Involved in Fibrillar Collagen Degradation

Dual drug delivery collagen vehicles for modulation of skin fibrosis in vitro

Activation of PTH1 receptor using chimeric peptide templated in situ click reaction of nanobody conjugates

Design and Evaluation of a Polypeptide that Mimics the Integrin Binding Site for EDA Fibronectin to Block Profibrotic Cell Activity

Selective inhibition of prolyl 4-hydroxylases by bipyridinedicarboxylates

Novel Collagen Analogs with Multicopy Mucin-Type Sequences for Multifunctional Enhancement Properties Using SUMO Fusion Tags

Selective Inhibition of Collagen Prolyl 4-Hydroxylase in Human Cells

N-glycosylation controls trafficking, zymogen activation and substrate processing of proprotein convertases PC1/3 and subtilisin kexin isozyme-1